Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021
Provention Bio, Inc. (Nasdaq: PRVB) will release its first quarter 2021 financial results on May 6, 2021, before U.S. markets open. Following the earnings announcement, a conference call will take place at 8:00 am E.T. to discuss the results and provide corporate updates. The company is focused on developing therapies for immune-mediated diseases, with its lead candidate, teplizumab, having a Biologics License Application filed with the FDA to delay clinical type 1 diabetes progression in at-risk individuals.
- Biologics License Application for teplizumab filed with the FDA.
- Focus on developing therapies for immune-mediated diseases.
- None.
RED BANK, N.J., April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
To access the call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contacts:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-first-quarter-2021-financial-results-on-may-6-2021-301280603.html
SOURCE Provention Bio, Inc.
FAQ
When will Provention Bio report its first quarter 2021 financial results?
What time will the conference call for Provention Bio's financial results take place?
What is Provention Bio's lead investigational drug candidate?
What disease is teplizumab aimed to delay the progression of?
Where can I access Provention Bio's conference call?
